BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Truist Financial

Truist Financial started coverage on shares of BioNTech (NASDAQ:BNTX) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $172.00 price objective on the stock.

A number of other research firms have also recently commented on BNTX. TD Cowen cut their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Wells Fargo & Company initiated coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Deutsche Bank Aktiengesellschaft upped their price objective on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Trading Up 0.6 %

BioNTech stock opened at $122.85 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market cap of $29.45 billion, a P/E ratio of -58.50 and a beta of 0.18. The firm’s fifty day moving average price is $114.07 and its 200-day moving average price is $103.06.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.73 EPS. Equities research analysts forecast that BioNTech will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC increased its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC bought a new stake in shares of BioNTech in the 3rd quarter worth approximately $59,485,000. Point72 Asset Management L.P. increased its stake in shares of BioNTech by 283.5% during the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares during the period. Braidwell LP purchased a new position in shares of BioNTech during the third quarter valued at approximately $29,425,000. Finally, New York State Common Retirement Fund raised its holdings in shares of BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock valued at $25,900,000 after acquiring an additional 178,981 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.